National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 2 of 1989)

Overview

The National Health Act 1953, enacted by the Parliament of Australia, was introduced to provide for the administration of national health and medical insurance schemes, as well as to facilitate access to essential pharmaceutical benefits for the Australian public. This legislation aimed to address the gap in affordable access to medications by establishing the Pharmaceutical Benefits Scheme (PBS), which provides subsidised prescription medications to Australian residents. The National Health Act 1953 serves as the foundational legal framework for the PBS, ensuring that necessary drugs and medicinal preparations are available and affordable to the public, thus promoting better health outcomes across the nation. On 1 April 1989, a declaration under sub-section 85 (2AA) of the Act was issued by Ian James McNeil, the First Assistant Secretary of the Health Benefits Division and Delegate of the Minister of State for Community Services and Health. This declaration specified certain drugs and medicinal preparations, such as Ammonium Chloride B.P., Benzyl Benzoate B.P., Intraperitoneal Dialysis Solutions B.P., and Sulphadimidine Tablets B.P., which were to cease being subject to Part VII of the National Health Act 1953. The policy objective behind this declaration was to refine and adjust the scope of the Pharmaceutical Benefits Scheme, ensuring that it remains efficient and responsive to the evolving healthcare needs of the Australian population.

Scope and Application

The Pharmaceutical Benefits Declaration under sub-section 85 (2AA) of the National Health Act 1953, made by Ian James McNeil, First Assistant Secretary, Health Benefits Division, Department of Community Services and Health, outlines specific pharmaceutical products that will no longer be covered under the Pharmaceutical Benefits Scheme (PBS) from 1 April 1953. This legislative instrument applies to the entities and individuals who are subject to the National Health Act 1953, including pharmaceutical manufacturers, suppliers, and consumers who are reliant on the PBS for drug subsidies. The geographic reach of this Act is national, impacting all states and territories within the Commonwealth of Australia. The Declaration identifies particular drugs and medicinal preparations listed in the Schedule, including Ammonium Chloride B.P., Benzyl Benzoate B.P., Intraperitoneal Dialysis Solutions B.P., and Sulphadimidine Tablets B.P., which will no longer be covered under Part VII of the National Health Act 1953. This exclusion from the PBS is effective as of the date specified, removing these products from the list of subsidised medicines. The scope of the Act does not extend beyond the specified medications listed in the Schedule, and no additional exclusions, exemptions, or thresholds are noted beyond what is explicitly stated in the Declaration.

Key Provisions

This Declaration under sub-section 85(2AA) of the National Health Act 1953, made by Ian James McNeil, First Assistant Secretary of the Health Benefits Division and Delegate of the Minister of State for Community Services and Health, specifies that certain drugs and medicinal preparations will no longer be subject to Part VII of the Act as of 1 April 1989. The primary operative sections of this Declaration are sections 1 and 2, which establish the effective date and the list of pharmaceutical products that will cease to be covered by the Act. Specifically, the listed drugs and medicinal preparations—Ammonium Chloride B.P., Benzyl Benzoate B.P., Intraperitoneal Dialysis Solutions B.P. C 1973, and Sulphadimidine Tablets B.P.—will no longer be subject to the provisions outlined in Part VII of the National Health Act 1953. The obligations and requirements imposed by this Act primarily concern the Department of Community Services and Health and its delegate, Ian James McNeil. They are responsible for ensuring that the changes outlined in the Declaration are communicated effectively and implemented accurately. The Act requires the delegate to notify relevant stakeholders of the changes, which include updating any internal systems and databases to reflect the new status of the listed pharmaceutical products. Additionally, any entities or individuals involved in the distribution, sale, or provision of these pharmaceutical products must be informed to ensure compliance with the changes. The Act does not explicitly detail offences, penalties, or consequences for breaches within this specific legislative instrument. However, in general, any non-compliance with the provisions of the National Health Act 1953 could result in penalties under the Act. These could include fines, imprisonment, or other civil or criminal sanctions depending on the nature and severity of the breach. The specific penalties would be determined based on the relevant sections of the broader Act that govern the pharmaceutical benefits scheme and the circumstances of any non-compliance. It is important for all parties involved to adhere to the requirements and changes specified in this Declaration to avoid any potential legal repercussions.